The FDA approved the quadruplet regimen on July 30 for induction and consolidation therapies in patients with newly diagnoses multiple myeloma who are eligible for autologous stem cell transplant.
Daratumumab and hyaluronidase-fihj is now FDA-approved for newly diagnosed multiple myeloma patients ineligible for ASCT, in combination with VRd. The phase 3 CEPHEUS trial showed significant ...
Johnson & Johnson seeks FDA approval for Darzalex Faspro-based regimen (D-VRd) for newly diagnosed multiple myeloma patients ineligible for stem cell transplant. Phase 3 CEPHEUS study shows D-VRd ...
January 27, 2026: The U.S. Food and Drug Administration (FDA) approved the quadruplet therapy daratamumab and hyaluronidase-fihj (Darzalex Faspro) in combination with bortezomib, lenalidomide, and ...
Darzalex addition to VRd improves MRD negativity and PFS in transplant-ineligible multiple myeloma patients, supporting its use as standard care. The CEPHEUS trial showed a 50% increase in MRD ...
Daratumumab, a monoclonal antibody targeting CD38, has been approved for use with standard myeloma regimens. An evaluation of subcutaneous daratumumab combined with bortezomib, lenalidomide, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results